Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
Gillette
Archived
•
November 8, 2026
•
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4WSINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) after 12-week treatment,…
Source: Gillette News Record | https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



